Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study
CA19-9 is a tumor marker for pancreatic cancer (PC), and the nondiabetic cut-off level is 37 U/mL. CA19-9 levels are said to rise in patients with tumors like PC and intraductal papillary mucinous neoplasm (IPMN). CA19-9 levels have also been shown to be related to HbA1c levels. We hypothesized that...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2023-11-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/70/11/70_EJ23-0186/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591721242820608 |
|---|---|
| author | Taku Yamada Taichi Minami Masayo Yamada Yasuo Terauchi |
| author_facet | Taku Yamada Taichi Minami Masayo Yamada Yasuo Terauchi |
| author_sort | Taku Yamada |
| collection | DOAJ |
| description | CA19-9 is a tumor marker for pancreatic cancer (PC), and the nondiabetic cut-off level is 37 U/mL. CA19-9 levels are said to rise in patients with tumors like PC and intraductal papillary mucinous neoplasm (IPMN). CA19-9 levels have also been shown to be related to HbA1c levels. We hypothesized that the CA19-9 cut-off levels would differ between patients with poorly controlled diabetes. This real-world trial was designed to test our hypotheses. This was a retrospective cohort study. All inpatients with poorly controlled diabetes had mean HbA1c levels of 10.0% and were divided into three groups: those with pancreatic cancer (PC group, N = 20), those with IPMN (IPMN group, N = 55), and those with neither (NC group, N = 985). Serum CA19-9 levels in the PC group were significantly higher than in the IPMN and NC groups (p < 0.001). CA19-9 levels did not differ statistically between the IPMN and NC groups. According to the receiver operating characteristic (ROC) analysis, serum CA19-9 levels of 98.4 U/mL had the highest sensitivity and specificity to detect PC, when comparing PC to IPMN + NC groups. Using this cut-off, the sensitivity and specificity of CA19-9 for PC were 70.0% and 96.5%, respectively, with a 0.81 area under the ROC curve. CA19-9 levels in two inpatients were >98.4 U/mL, most likely due to hepatocellular carcinoma and esophageal cancer. CA19-9 cut-off levels were thought to be 98.4 U/mL. However, we should keep in mind that the sensitivity and specificity were not 100%. |
| format | Article |
| id | doaj-art-a23c813f73f745649a300c0099858827 |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2023-11-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-a23c813f73f745649a300c00998588272025-01-22T06:23:18ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402023-11-0170111069107510.1507/endocrj.EJ23-0186endocrjProposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world studyTaku Yamada0Taichi Minami1Masayo Yamada2Yasuo Terauchi3Department of Diabetes and Endocrinology, Saiseikai Yokohamashi Nanbu Hospital, Yokohama 234-0054, JapanDepartment of Diabetes and Endocrinology, Saiseikai Yokohamashi Nanbu Hospital, Yokohama 234-0054, JapanDepartment of Internal Medicine, Division of Metabolism and Endocrinology, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, Yokohama 247-0005, JapanDepartment of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, JapanCA19-9 is a tumor marker for pancreatic cancer (PC), and the nondiabetic cut-off level is 37 U/mL. CA19-9 levels are said to rise in patients with tumors like PC and intraductal papillary mucinous neoplasm (IPMN). CA19-9 levels have also been shown to be related to HbA1c levels. We hypothesized that the CA19-9 cut-off levels would differ between patients with poorly controlled diabetes. This real-world trial was designed to test our hypotheses. This was a retrospective cohort study. All inpatients with poorly controlled diabetes had mean HbA1c levels of 10.0% and were divided into three groups: those with pancreatic cancer (PC group, N = 20), those with IPMN (IPMN group, N = 55), and those with neither (NC group, N = 985). Serum CA19-9 levels in the PC group were significantly higher than in the IPMN and NC groups (p < 0.001). CA19-9 levels did not differ statistically between the IPMN and NC groups. According to the receiver operating characteristic (ROC) analysis, serum CA19-9 levels of 98.4 U/mL had the highest sensitivity and specificity to detect PC, when comparing PC to IPMN + NC groups. Using this cut-off, the sensitivity and specificity of CA19-9 for PC were 70.0% and 96.5%, respectively, with a 0.81 area under the ROC curve. CA19-9 levels in two inpatients were >98.4 U/mL, most likely due to hepatocellular carcinoma and esophageal cancer. CA19-9 cut-off levels were thought to be 98.4 U/mL. However, we should keep in mind that the sensitivity and specificity were not 100%.https://www.jstage.jst.go.jp/article/endocrj/70/11/70_EJ23-0186/_html/-char/endiabetes mellituscarbohydrate antigen 19-9 (ca19-9)pancreatic cancer |
| spellingShingle | Taku Yamada Taichi Minami Masayo Yamada Yasuo Terauchi Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study Endocrine Journal diabetes mellitus carbohydrate antigen 19-9 (ca19-9) pancreatic cancer |
| title | Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study |
| title_full | Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study |
| title_fullStr | Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study |
| title_full_unstemmed | Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study |
| title_short | Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study |
| title_sort | proposed carbohydrate antigen 19 9 ca19 9 cut off values for the detection of pancreatic cancer in patients with poorly controlled diabetes a real world study |
| topic | diabetes mellitus carbohydrate antigen 19-9 (ca19-9) pancreatic cancer |
| url | https://www.jstage.jst.go.jp/article/endocrj/70/11/70_EJ23-0186/_html/-char/en |
| work_keys_str_mv | AT takuyamada proposedcarbohydrateantigen199ca199cutoffvaluesforthedetectionofpancreaticcancerinpatientswithpoorlycontrolleddiabetesarealworldstudy AT taichiminami proposedcarbohydrateantigen199ca199cutoffvaluesforthedetectionofpancreaticcancerinpatientswithpoorlycontrolleddiabetesarealworldstudy AT masayoyamada proposedcarbohydrateantigen199ca199cutoffvaluesforthedetectionofpancreaticcancerinpatientswithpoorlycontrolleddiabetesarealworldstudy AT yasuoterauchi proposedcarbohydrateantigen199ca199cutoffvaluesforthedetectionofpancreaticcancerinpatientswithpoorlycontrolleddiabetesarealworldstudy |